Li Zaiping
Li Zaiping (Chinese: 李载平; 17 August 1925 – 30 May 2018) was a Chinese molecular biologist considered a pioneer in genetic science and engineering in China. His research team was the first in China to sequence a virus genome. He also utilized E. coli to produce human EGF and GM-CSF, and identified the gene LPTS. He was a professor at the Shanghai Institute of Biochemistry and Cell Biology and an academician of the Chinese Academy of Engineering.
Biography[edit]
Li was born in Beijing on 17 August 1925. He graduated from the Department of Chemistry of Peking University in 1947, and became a lecturer of biochemistry at PKU.[1] In 1956, he was admitted as a graduate student to the Shanghai Institute of Biochemistry, where he studied under the academician Cao Tianqin.[2] After graduation in 1960, he founded China's first laboratory for molecular DNA and genetics research at the Shanghai institute. He became a full professor in 1977.[2]
Li's group was the first to sequence the full genomic DNA of pADR-1, the most prevalent subtype of hepatitis B virus in China. It was the first time a virus genome was sequenced in China.[1] The research resulted in the development of a highly effective recombinant hepatitis B vaccine.[1] In another project, he utilized a secretive gene expression system in Escherichia coli to produce human EGF and human GM-CSF, both of which have been approved for medical use. He also identified a new gene called liver-related putative tumor suppressor (LPTS) in chromosome 8p23.[1]
He published more than 200 research papers and won more than 10 national and international prizes[2] including the first-class National Prize of Progress in Science and Technology (three times)[2] and the Ho Leung Ho Lee Prize for Life Sciences.[1] He was elected as an academician of the Chinese Academy of Engineering in 1996.[2]
Li died at Zhongshan Hospital in Shanghai on 30 May 2018, aged 92.[2]